ORTHOCELL LTD

Orthocell’s sharp 12.5% drop follows a strong quarter led by Remplir’s U.S. sales surge, yet market sentiment remains cautious amid volatility and a 200‑day SMA gap.

Orthocell Ltd’s shares slid 7.7% to AUD 0.53, dropping 16% from last month’s close. Explore its biotech focus on tendon repair and market trends.

Orthocell drops 2.99% as market sentiment cools, yet its tendon‑repair pipeline still offers upside; track clinical milestones and partners for future gains.

Orthocell Ltd (OCC.AX) shares dip 2.99% to AUD 0.65, trading below its 52‑week low, while the biotech firm continues focusing on tendon & ligament repair solutions.